Richard Alan Rudick Purchases IMUX Shares

Richard Alan Rudick recently bought 25,370 shares of IMUX on June 29, 2026. This insider transaction did not involve a pre-planned trading scheme, indicating a direct purchase decision by Rudick. The stock was trading near $15.30 on Tuesday, reflecting the market's current valuation.

Other Institutional Activity in IMUX

Several other funds have adjusted their positions in IMUX. Aberdeen Group PLC reduced its holdings significantly by 7,419,547 shares, ending with 824,394 shares valued at approximately $9.15 million. BVF Inc/IL also cut its stake by 6,887,675 shares, holding 765,297 shares worth about $8.49 million. Avidity Partners Management LP decreased its position by 4,029,470 shares to 669,941 shares, valued at $7.44 million. Meanwhile, Vanguard Capital Management LLC and Soleus Capital Management, L.P. both opened new positions, with Vanguard holding 513,832 shares valued at around $5.70 million and Soleus holding 450,000 shares worth $4.99 million.

Immunic, Inc. Stock Up 0.1%

Shares of IMUX traded near $15.30 on Tuesday. The company has been seeing some volatility, with a number of institutional investors adjusting their holdings. The stock's performance is being closely watched by analysts and investors alike.

Insider Buying and Selling at Immunic, Inc.

In addition to Richard Alan Rudick's purchase, several other insiders bought shares on June 29, 2026. Jon Congleton acquired 50,740 shares, while Jason Tardio, the President and COO, bought 253,000 shares. Glenn Whaley, the Chief Financial Officer, purchased 120,000 shares. Joerg Neermann and Tamar Howson each bought 25,370 shares, and Daniel Vitt acquired 445,000 shares. These purchases were not made under pre-planned trading programs, suggesting confidence in the company's prospects.

Analysts Set New Price Targets

Analyst activity has been positive for IMUX. On May 22, 2026, B. Riley Securities maintained a 'buy' rating with a price target of $27. HC Wainwright & Co. also maintained a 'buy' rating with a $22 target on April 30, 2026. Stifel initiated coverage with a 'buy' rating and a $2.5 target on April 17, 2026. The consensus among analysts is a 'buy' recommendation, with an average target price reflecting optimism about the company's future.

Bottom Line

Richard Alan Rudick's recent purchase of IMUX shares is part of broader insider buying activity that suggests confidence in the company's future. The stock's trading activity and analyst ratings highlight ongoing interest and potential growth. Investors will continue to monitor IMUX's performance and institutional moves as key indicators of its market position.